## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

wasnington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average b	urden									
-	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							( )				' '									
Name and Address of Reporting Person*     Lo Steven						2. Issuer Name and Ticker or Trading Symbol  CORCEPT THERAPEUTICS INC [ CORT ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify					
(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS 149 COMMONWEALTH DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 11/16/2015									X Office (give title Offier (specify below)  SVP Oncology					
(Street) MENLO PARK CA 94025						If Am	endment, [	Date o	of Original	Filed	(Month/Da		Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person							
(City)	(5	State)	(Zip)																	
1. Title of S	Security (Ins		ıble I - No	2. Tra	rivati nsaction	n	2A. Deeme	ed	3.		4. Securit	ies Acquire	ed (A) or	5. Am	ount of			7. Nature of		
					Date Month/Day/Year)		Execution Date, if any (Month/Day/Year)		Code (I	Transaction Code (Instr.		Disposed Of (D) (Instr. 3, 4		Benef Owne	Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	r Indirect E str. 4) C	Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) oi (D)	Price	Transa	action(s) 3 and 4)					
Common stock			11/	16/201	15			M		113,96	0 A <sup>(1)</sup>	\$3.	51 1	113,960		D				
Common stock			11/	16/201	15			M		286,04	0 A <sup>(1)</sup>	\$3.	51 4	00,000	),000					
Common stock				11/	/16/2015				M		33,333	3 A <sup>(1)</sup>	\$2.	.7 4	33,333		D			
Common stock				11/	16/201	15			M		64,583	3 A <sup>(1</sup>	A <sup>(1)</sup> \$2.07		5 497,916		D			
Common stock 11/10				16/201	/2015		M	87,50		) A <sup>(1</sup>	\$1.5	585,416			D					
			Table II -								osed of			y Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution E if any (Month/Day	Date,	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercis Expiration Date (Month/Day/Yea		е	7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		Derivati Security		ve es ally ig	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Share		(Instr. 4)	on(s)				
Stock option	\$3.51	11/16/2015			M		113,960		(2)		09/23/2020	Common stock	113,96	0 \$3.51	0		D			
Stock option	\$3.51	11/16/2015			М		286,040		(2)		09/23/2020	Common stock	286,04	0 \$3.51	0		D			
Stock option	\$2.7	11/16/2015			M		33,333		(2)		10/09/2022	Common stock	33,333	\$2.7	0		D			
Stock option	\$2.075	11/16/2015			M		64,583		(2)		01/29/2023	Common stock	64,583	\$2.075	0		D			
Stock	\$1.92	11/16/2015			M		87,500		(2)		11/18/2023	Common	87,500	\$1.92	0		D			

## **Explanation of Responses:**

- 1. Exercise and hold.
- 2. Fully exerciseable.

## Remarks:

/s/ Joseph K. Belanoff, CEO of Corcept Therapeutics

Incorporated attorney-in-fact

stock

11/16/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.